
Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery
by Vall d'Hebron Institute of OncologyCholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers
Updated on: January 08,2024
10

Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery
by Vall d'Hebron Institute of OncologyCholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers
Updated on:January 08,2024
10
